Page last updated: 2024-12-11

inecalcitol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6915835
CHEMBL ID2105107
SCHEMBL ID754593
MeSH IDM0573334

Synonyms (31)

Synonym
(7e)-(1r,3r,14r)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol
19-nor-14-epi-23-yne-1,25 dihydroxyvitamin d3
LMST03020649
(7e)-19-nor-9,10-seco-14beta-cholesta-5,7-dien-23-yne-1alpha,3beta,25-triol
inecalcitol ,
DB04796
(1r,3r)-5-[(2e)-2-[(1r,3ar,7ar)-1-[(2r)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
AC1OCD0K ,
tx-527
tx 522
tx527 cpd
tx 527
tx-522
163217-09-2
05fzv98342 ,
unii-05fzv98342
inecalcitol [inn]
CHEMBL2105107
tx522
9,10-seco-14bh-19-norcholesta-5(z),7(e)-dien-1(r),3(r),25-triol-23-yne
1,3-cyclohexanediol, 5-((2e)-2-((1r,3ar,7ar)-octahydro-1-((1r)-5-hydroxy-1,5-dimethyl-3-hexyn-1-yl)-7a-methyl-4h-inden-4-ylidene)ethylidene)-, (1r,3r)-
(7e)-19-nor-9,10-seco-14.beta.-cholesta-5,7-dien-23-yne-1.alpha.,3.beta.,25-triol
gtpl7747
SCHEMBL754593
AKOS025312295
Q27078058
MS-26815
EX-A5555
DTXSID60870084
CS-0001525
HY-32344

Research Excerpts

Overview

Inecalcitol is a novel vitamin D receptor agonist with higher antiproliferative effects and a 100-fold lower hypercalcemic activity than calcitriol.

ExcerptReferenceRelevance
"Inecalcitol is a novel vitamin D receptor agonist with higher antiproliferative effects and a 100-fold lower hypercalcemic activity than calcitriol."( Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients.
Allyon, J; Deplanque, G; Dufour-Lamartinie, JF; Elaidi, R; Ferrero, JM; Houillier, P; Lerest, C; Mackenzie, S; Maruani, G; Maurina, T; Medioni, J; Oudard, S; Raymond, E; Renaux, S; Rodier, JM, 2014
)
1.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (39.13)29.6817
2010's14 (60.87)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.49 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index5.41 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.35%)5.53%
Reviews3 (13.04%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (82.61%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]